Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Site-Targeted Drug Delivery Systems: Polymeric Carriers01:24

Site-Targeted Drug Delivery Systems: Polymeric Carriers

Polymeric carriers enhance targeted drug delivery by increasing efficacy while minimizing off-target effects. These carriers comprise a biodegradable polymeric backbone integrated with functional elements that enable targeting, improve physicochemical properties, and regulate drug release.Targeting MechanismsThe targeting ability of polymeric carriers is mediated by a homing device, which is a molecular recognition component designed to selectively bind to specific tissues or cells. Monoclonal...
Phase II Conjugation Reactions: Overview01:14

Phase II Conjugation Reactions: Overview

Conjugation, a key component of phase II biotransformation reactions, is a vital process in drug detoxification. It involves transferring endogenous substances like glucuronic acid, sulfate, and glycine to drugs or their metabolites formed in phase I reactions. These conjugation reactions, often catalyzed by specific enzymes, transform potentially harmful metabolites into inactive, water-soluble forms easily excreted in urine or bile. By enhancing polarity and eliminating pharmacological...
Modified-Release Drug Delivery Systems: Rate-Programmed II01:19

Modified-Release Drug Delivery Systems: Rate-Programmed II

Rate-programmed drug delivery systems release drugs in a controlled manner to maintain therapeutic levels. Three main designs include reservoir, matrix, and hybrid systems.Reservoir systems consist of a drug core enclosed within a membrane that controls drug release. In non-swelling reservoir systems, polymers like ethyl cellulose or polymethacrylates are used. These do not hydrate in aqueous media and control release through membrane thickness, porosity, or insolubility. This type includes...
Modified-Release Drug Delivery Systems: Classification01:23

Modified-Release Drug Delivery Systems: Classification

Modified-release drug delivery systems improve drug efficacy and minimize side effects by controlling the rate and location of drug release. These systems fall into three categories: rate-programmed, stimuli-activated, and site-targeted.Rate-programmed systems release drugs at a predetermined rate, maintaining consistent therapeutic levels and reducing fluctuations that could lead to toxicity or subtherapeutic effects. These systems use polymeric matrices, reservoir-based designs, or osmotic...
Modified-Release Drug Delivery Systems: Site-Targeted01:24

Modified-Release Drug Delivery Systems: Site-Targeted

Site-targeted drug delivery systems enhance therapeutic efficacy while minimizing systemic toxicity and treatment costs. Unlike conventional methods, these systems ensure precise drug delivery, improving bioavailability and reducing side effects. Targeted drug delivery is classified into three levels. First-order targeting directs drugs to the capillary beds of specific organs or tissues. Second-order targets specific cell types, such as tumor cells, using receptor-mediated interactions.
Bioavailability Enhancement: Drug Stability Enhancement and GI Retention01:05

Bioavailability Enhancement: Drug Stability Enhancement and GI Retention

Improving a drug's stability in the gastrointestinal (GI) tract is paramount for enhancing its bioavailability and therapeutic effectiveness. Various strategies are employed to protect the drug from the harsh gastric milieu and to ensure its release and absorption at the desired site within the GI tract.Polymer coatings are one such method used to shield drugs from the stomach's acidic environment. By preventing premature drug release, these coatings improve the bioavailability of unstable...

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

In vivo dosimetry using an electronic portal imaging device for pediatric myeloablative Total body irradiation with volumetric modulated arc therapy.

Physics and imaging in radiation oncology·2026
Same author

TTP-like syndrome revealing advanced HIV infection: a case of secondary multifactorial thrombotic microangiopathy.

MedScience·2026
Same author

Muscular Fitness Components in Adults With Type 1 Diabetes: A Cross-Sectional Study.

Diabetes/metabolism research and reviews·2026
Same author

A multi-method study of unlicensed medicine risk assessment: a cross-sectional survey of pharmacy procurement leads and policy analysis across NHS trusts in England.

International journal of clinical pharmacy·2026
Same author

Biodegradable cross-linked flavone networks featuring either ester or carbamate linkages for controlled delivery of anti-cancer agents.

RSC advances·2026
Same author

Effects of physical exercise on menstrual symptoms in polycystic ovary syndrome: a systematic review.

Journal of endocrinological investigation·2026

Related Experiment Video

Updated: Jul 10, 2026

Preparation and Characterization of Individual and Multi-drug Loaded Physically Entrapped Polymeric Micelles
07:32

Preparation and Characterization of Individual and Multi-drug Loaded Physically Entrapped Polymeric Micelles

Published on: August 28, 2015

Polymer-drug conjugates: current status and future trends.

Francesca Greco1, Maria J Vicent

  • 1School of Pharmacy, University of Reading, Whiteknights, PO BOX 224, Reading RG6 6AD, Berkshire, UK.

Frontiers in Bioscience : a Journal and Virtual Library
|November 6, 2007
PubMed
Summary

Polymer conjugates, used in cancer therapy, show promise for solid tumors by improving drug delivery. Further development of these nanomedicines is crucial for realizing their full therapeutic potential.

More Related Videos

Formulation of Diblock Polymeric Nanoparticles through Nanoprecipitation Technique
06:47

Formulation of Diblock Polymeric Nanoparticles through Nanoprecipitation Technique

Published on: September 20, 2011

Related Experiment Videos

Last Updated: Jul 10, 2026

Preparation and Characterization of Individual and Multi-drug Loaded Physically Entrapped Polymeric Micelles
07:32

Preparation and Characterization of Individual and Multi-drug Loaded Physically Entrapped Polymeric Micelles

Published on: August 28, 2015

Formulation of Diblock Polymeric Nanoparticles through Nanoprecipitation Technique
06:47

Formulation of Diblock Polymeric Nanoparticles through Nanoprecipitation Technique

Published on: September 20, 2011

Area of Science:

  • Nanomedicine
  • Oncology
  • Polymer Chemistry

Background:

  • Polymer conjugates are nano-sized, multi-component constructs utilized in clinical anticancer treatments.
  • They offer potential for improved pharmacological therapy in various solid tumors.

Purpose of the Study:

  • To review clinical trial results of polymer-bound chemotherapy.
  • To discuss the foundation for developing next-generation polymer conjugates.
  • To highlight ongoing challenges and future directions in polymer therapeutics.

Main Methods:

  • Analysis of clinical trial data for polymer-bound chemotherapy.
  • Review of the enhanced permeability and retention (EPR) effect in tumor targeting.
  • Discussion of lysosomotropic drug delivery mechanisms.

Main Results:

  • Clinical trials show promising results for polymer-bound chemotherapy agents.
  • Experience from current trials informs the development of advanced polymer conjugates.
  • The polymer therapeutics platform enables innovation in materials and drug incorporation.

Conclusions:

  • Rational design of polymer drug conjugates is key to unlocking their potential as nanomedicines.
  • Further refinement of this technology platform is needed to overcome existing challenges.
  • Polymer conjugates represent a significant advancement in anticancer drug therapy.